Galectin Therapeutics GALTW 深 沪
已收盘 10-08 16:00:00 美东时间
0.0425
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0425
- 总市值 0
- 52周最高 0.254
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 0.024
- 委 比 0.00%
- 总股本 --
- 历史最高 0.254
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.024
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Galectin Therapeutics Announces Positive Feedback From Recent In Person Type C Meeting With FDA For Its Belapectin To Treat Patients With Metabolic Dysfunction-associated Steatohepatitis Cirrhosis, Portal Hypertension
Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies for patients with advanced liver disease, today announced positive feedback from its recent in person Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of bela...
06-23 20:09
Galectin Therapeutics to file Phase 3 belapectin protocol in Q3 2026 for MASH cirrhosis, portal hypertension
Galectin Therapeutics to file Phase 3 belapectin protocol in Q3 2026 for MASH cirrhosis, portal hypertension Galectin Therapeutics reported FDA Type C meeting alignment to advance belapectin into a Phase 3 trial for MASH cirrhosis with portal hypertension. No new clinical results were presented; the
06-23 19:51
Cartesian Therapeutics Announces Non-Dilutive Financing Of Up To $150M From K2 HealthVentures; Expects Topline Data From Phase 3 AURORA Trial In Q1 2027
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that it has entered into an agreement with K2
05-26 19:05
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
Cartesian Therapeutics secured $150 million in non-dilutive financing from K2 HealthVentures, with an initial $50 million tranche extending its cash runway into 2028. The funding will support clinical programs for myasthenia gravis (MG) and myositis, with key data readouts expected in 2027, including Phase 3 AURORA trial results in Q1, Phase 2 TRITON data in H1, and Phase 1/2 HELIOS pediatric trial data in H1. The company also announced the depar...
05-26 11:00
Galectin Therapeutics Q1 EPS $(0.08) Misses $(0.06) Estimate
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 46.67 percent increase over losses of $(0.15) per
05-15 20:13
Galectin Therapeutics Announces Publication Of Results From NAVIGATE Phase 2b Clinical Trial Evaluating Belapectin In Patients With MASH Cirrhosis And Portal Hypertension In AASLD Flagship Journal Hepatology
Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced the
05-11 20:07
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
Galectin Therapeutics Inc. announced the publication of Phase 2b NAVIGATE trial results in Hepatology, showing belapectin reduces new esophageal varices in MASH cirrhosis and portal hypertension patients. The study demonstrated a numerical reduction in variceal development with belapectin 2 mg/kg vs. placebo, statistically significant in the per-protocol population. Non-invasive biomarkers and safety data supported the findings. Galectin plans to...
05-11 12:00
Galectin Therapeutics Q4 EPS $(0.08) Beats $(0.11) Estimate
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 57.89 percent increase over losses of $(0.19) per share
03-31 22:19
Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs
Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs Overview U.S. biotech's 2025 net loss narrowed as R&D expenses declined after NAVIGATE trial end Company ended 2025 with $17.7 mln cash plus $10 mln credit line, extending runway to April 2027 Outlook Company expe
03-31 20:09
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
Galectin Therapeutics reported that its belapectin program, targeting galectin-3, showed progress in reducing varices and positive biomarker data in patients with MASH cirrhosis. The company secured an additional $10 million line of credit, bolstered its board with Dr. Henry Brem, and saw improved financial stability with reduced R&D expenses, narrowing its net loss.
03-31 12:00
